Latest articles by Dr Mike Tubbs
-
Mpac Group: making steady profits from premium packaging
Tips Mpac Group’s automated packaging machines are sold to blue-chip clients in more than 80 countries worldwide. Dr Mike Tubbs looks at the company's potential for investors.
Tips -
Vanquishing the virus: the race to make vaccines for Covid-19
Cover Story The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews the story and explains what it means for investors.
Cover Story -
Novo Nordisk: Denmark’s dominant drug maker
Tips Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
Tips -
How to profit from the development of new auto-immune disease drugs
Tips Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals market.
Tips -
Lessons for investors from Big Tech's previous golden era
Analysis The forerunners of today's tech stock titans dominated the 1960s and 1970s. Former Xerox senior manager Dr Mike Tubbs was there and explains what investors can learn from those companies' mistakes.
Analysis -
Healthy profits: how to make money from investing in medical technology
Cover Story There’s far more to the health sector than whizzy new pills, says Dr. Mike Tubbs. He reviews the latest developments in areas ranging from robotic surgery to joint replacements and suggests some top stocks.
Cover Story -
Lockheed Martin: the world’s best defence stock
Tips Lockheed Martin is the industry’s most diversified top-quality company and a robust pick in tough times.
Tips -
Where to find "ten-bagger" stocks – the market's Holy Grail
Cover Story “Ten-baggers,” stocks with the potential to rise tenfold, are rare but not impossible to find. Dr Mike Tubbs explores their key characteristics and suggests where you should start your search
Cover Story -
Gilead's anti-viral expertise will stand it well
Tips There is far more to biotech giant Gilead Sciences than its potential treatment for Covid-19; it has expertise in anti-virals against a wide range of the world’s dangerous diseases.
Tips -
This high quality engineering firm will filter profits to investors
Tips Porvair, a maker of high-tech filtration systems, is an excellent long-term pick for your investment portfolio.
Tips -
Secret sauce: the key to serial innovation and profit growth
Cover Story Why do some companies fizzle out and fade away while others build on a strong start? Dr Mike Tubbs looks at the key factors behind sustainable success and highlights his favourite consistent performers.
Cover Story -
Stocks that offer two sectors for the price of one
Analysis There are several excellent companies that dabble in two very different markets. Dr Mike Tubbs highlights the ones worth considering now.
Analysis -
How stem cells are changing the face of medicine
Features We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs explores recent breakthroughs and assesses the state of the market.
Features -
Engineering profits: the British industrial champions to buy now
Cover Story Move over, Germany and Sweden. There are several world-class UK engineers in profitable niches supplying a vast array of industries with vital equipment. Dr Mike Tubbs picks his favourites.
Cover Story -
Swedish engineer Hexagon is in excellent shape
Features This Swedish engineer has been overshadowed by bigger local peers, but is well worth a look
Features -
Where to find and how to invest in founder-managed firms
Tutorials Companies that are set up and then run by the same person for a long time tend to be lucrative investments. Dr Mike Tubbs explains why, how to find founder-managed firms, and which ones to buy now.
Tutorials -
Diploma qualifies for your portfolio
Features This British mid-cap is a successful global player with plenty of room for expansion, says Dr Mike Tubbs.
Features -
Immunotherapy: new hope in the battle against cancer
Cover Story Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors can benefit too.
Cover Story -
Alexion: a rare opportunity in biotech
Features Alexion focuses on diseases that affect only a tiny proportion of the population – a lucrative niche.
Features -
Illumina: shedding light on genetics
Features Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.
Features -
R&D: the key to long-term sales and profit growth
Tutorials Companies that spend heavily on research and development (R&D) greatly improve their long-term odds. Dr Mike Tubbs explains what to look out for – and what to buy now.
Tutorials -
The strong and stable stocks offering a reliable income
Tutorials Companies with a consistent record of rising payouts look especially attractive at present. Dr Mike Tubbs introduces his favourite “dividend aristocrats”.
Tutorials -
Profit from Renishaw’s precision
Features Few people have heard of Renishaw, but its products and prospects are excellent, says Mike Tubbs.
Features -
Salesforce: software service with a smile
Features Salesforce, one of the world’s top software companies, has a bright future and is currently on sale.
Features
